C1

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

Dyadic Announces Change in Board and Management Leadership Roles

Retrieved on: 
Thursday, March 28, 2024
Dow Chemical Company, Partnership, Science, Food, C1, Protein, Trial of the century, Ligand Pharmaceuticals, Retirement, Therapy, Pharmaceutical industry

The Board has decided not to fill the vacancy due to Dr. Buckland’s retirement which will result in a reduction of the size of the Board from seven to six members.

Key Points: 
  • The Board has decided not to fill the vacancy due to Dr. Buckland’s retirement which will result in a reduction of the size of the Board from seven to six members.
  • Finally, Joseph Hazelton has been appointed Chief Operating Officer, effective immediately, and will oversee the day-to-day operations of the Company.
  • Mr. Lucy joined the Board in January 2021 and serves on the company’s Science and Technology Committee.
  • "I am excited to assume the role as Chairman of the Dyadic board of directors.

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Retrieved on: 
Tuesday, March 26, 2024
CHO, Science, Manuscript, C1, SARS-CoV-2, Infection, Clinical trial, Veterinary medicine, Safety, Vaccine, Nature Communications

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.

Key Points: 
  • The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.
  • "The study characterized the in vitro activity of a monoclonal antibody (mAb) produced by C1 cells (designated "HuMab 87G7") and demonstrated its protective efficacy for both prophylactic and therapeutic applications in hamsters and non-human primates without causing antibody-mediated enhanced virus replication.
  • A mounting body of evidence, from both ourselves and an expanding community of scientists worldwide, supporting the use of Dyadic's C1 expression system as a versatile production platform.
  • To view the online publication of “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models”, please visit nature communications or follow the link below:

WYBOTICS Release the WYBOT C1 Cordless Robotic Pool Cleaner

Retrieved on: 
Monday, April 1, 2024
PVC, Headache, Swimming, Filtration, News, Sand, GPH, C1, LOS, Multimedia, Online shopping

LOS ANGELES, April 1, 2024 /PRNewswire/ -- WYBOTICS, an innovator in the swimming pool cleaning and maintenance device world, recently celebrated the news its latest breakthrough is available, the WYBOT C1 Cordless Robotic Pool Cleaner for In-Ground Pools. This new piece of swimming pool tech represents an advancement over previous models, skyrocketing efficient "hands-free" cleaning for homeowners.

Key Points: 
  • LOS ANGELES, April 1, 2024 /PRNewswire/ -- WYBOTICS, an innovator in the swimming pool cleaning and maintenance device world, recently celebrated the news its latest breakthrough is available, the WYBOT C1 Cordless Robotic Pool Cleaner for In-Ground Pools .
  • The WYBOT C1 Cordless Robotic Pool Cleaner is designed to address the evolving needs of in-ground pool owners, offering a host of advanced features and enhancements over previous models.
  • Furthermore, the 2024 WYBOT C1 Cordless Robotic Pool Cleaner offers the convenience of scheduled cleaning through a dedicated app.
  • In conclusion, the launch of the 2024 WYBOT C1 Cordless Robotic Pool Cleaner represents a significant milestone in pool maintenance technology.

Hiboy to Launch Its First Folding Electric Bike: Hiboy C1 - The Perfect Blend of Style and Performance for a New Urban Riding Experience

Retrieved on: 
Thursday, March 28, 2024
Congestion, Smartphone, Hahn Hi-Boy, Acceleration, Electricity, Travel, Sale, Transport, C1, Safety, Air pollution, Maxima and minima

GLENDORA, Calif., March 27, 2024 /PRNewswire/ -- Hiboy has announced the launch of its first folding Electric bike - the Hiboy C1 .

Key Points: 
  • GLENDORA, Calif., March 27, 2024 /PRNewswire/ -- Hiboy has announced the launch of its first folding Electric bike - the Hiboy C1 .
  • This folding electric bike enhances the rider's riding style and performance for a fantastic urban riding experience while ensuring complete safety and security.
  • Hiboy's design philosophy for the C1 electric bike is to help the riding experience of urban commuters and showcase their personal style with comfort.
  • The Hiboy C1 folding bike can handle inclines smoothly with its different riding modes, i.e., electric and pedal assist.

NAVEE Unveils Strategic Partnerships with Drover AI and KNOT at the Autonomy Mobility World Expo 2024

Retrieved on: 
Tuesday, March 19, 2024
ARAS, Theft, D1, Intelligence, Partnership, Drover, Transport, KNOT, Software, C1, Safety, S1, Plan

PARIS, March 19, 2024 /PRNewswire/ -- NAVEE, an emerging leader in the sharing e-scooter and e-bike industry, is set to showcase its latest products at the Autonomy Mobility World Expo 2024 in Paris from March 20-21.

Key Points: 
  • PARIS, March 19, 2024 /PRNewswire/ -- NAVEE, an emerging leader in the sharing e-scooter and e-bike industry, is set to showcase its latest products at the Autonomy Mobility World Expo 2024 in Paris from March 20-21.
  • Renowned for highlighting sustainable urban transportation innovations, the expo provides the perfect stage for NAVEE to reveal its strategic partnerships with Drover AI, renowned for its AI-powered mobility technologies, and KNOT Charging Pile, a front-runner in electric vehicle charging solutions.
  • The partnership also enables NAVEE to leverage Drover AI's cutting-edge computer vision to elevate the intelligence, safety, and user experience of its E-scooters.
  • The partnerships with Drover AI and KNOT not only refine NAVEE's e-scooter and e-bike offerings but also contribute to a more sustainable, efficient, and connected urban mobility ecosystem.

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Retrieved on: 
Monday, March 11, 2024
Senior, Finance Secretary (India), Note, C1, Common stock, Growth, Sale, Common, Form, Health, Convertible, Clinical trial, Human, VWAP, Security (finance)

The Convertible Notes will be senior, secured obligations of Dyadic and its affiliates, and interest will be payable quarterly in cash on the principal amount equal to 8% per annum.

Key Points: 
  • The Convertible Notes will be senior, secured obligations of Dyadic and its affiliates, and interest will be payable quarterly in cash on the principal amount equal to 8% per annum.
  • The Convertible Notes will mature on March 8, 2027 (the “Maturity Date”), unless earlier converted, repurchased, or redeemed in accordance with the terms of the Convertible Notes.
  • The Convertible Notes will be convertible into shares of Dyadic’s Class A common stock (the “Common Stock”), at the option of the holders of the Convertible Notes (the “Noteholders”) at any time prior to the Maturity Date.
  • “I would like to extend our gratitude to long-term shareholders for their steadfast support.

Gabelli Utilities Fund Reaffirms $0.88 Distribution Policy and Announces Conversion of C1 Class

Retrieved on: 
Thursday, February 29, 2024
Prospectus, Investment, Class, C1, Class C, Fund, Policy, OTCQX, GAMCO Investors, Effective date, Security (finance)

GREENWICH, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Board of Trustees (the “Board”) of The Gabelli Utilities Fund (the “Fund”) reaffirmed the Fund’s annual distribution rate of $0.88 per share for Class I, Class A, Class AAA, and Class C shareholders.

Key Points: 
  • GREENWICH, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- The Board of Trustees (the “Board”) of The Gabelli Utilities Fund (the “Fund”) reaffirmed the Fund’s annual distribution rate of $0.88 per share for Class I, Class A, Class AAA, and Class C shareholders.
  • If Class C1 shares are not redeemed prior to the Effective Date, each shareholder owning Class C1 shares of the Fund will own Class C shares of the Fund equal to the aggregate value of the shareholder’s Class C1 shares.
  • Therefore, shareholders of Class C1 shares who do not redeem their Class C1 shares, and instead have their Class C1 shares converted into Class C shares, will own a fewer number of shares (but with the same aggregate dollar value) after such conversion.
  • Since the per share distribution of the Class C1 shares and the Class C shares is the same, shareholders whose shares are converted to Class C will receive a lower total distribution amount as Class C shareholders even though the per share amount will remain unchanged.

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Retrieved on: 
Wednesday, February 28, 2024
Incidence, Virology, LMIC, Vaccine, C1, SME, European, Dyadic, COVID-19, Innovation, Rabies, AVATAR, Disease, DRS, Research, Partnership

The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.

Key Points: 
  • The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.
  • This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives.
  • As per the strategic partnership agreement, Dyadic will receive an equity stake in, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
  • Punt highlighted the potential of combining advances in vaccinology with Dyadic's C1 protein production platform to accelerate research, enhance product development, and lower manufacturing costs.

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Retrieved on: 
Tuesday, February 6, 2024
C1, Traction, A-DNA, Global health, Dyadic, Research, Antibody, Vaccine

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform.

Key Points: 
  • JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform.
  • Under the agreement, research and development activities will be funded by the collaborator.
  • “Dyadic's C1 protein expression platform is gaining increased traction in research and development targeting infectious and other diseases,” said CEO Mark Emalfarb, "We are glad to see the progress of our C1-cell protein production platform for human and animal biopharmaceuticals and we believe the recent positive Phase I first in human data for a recombinant vaccine produced using C1 will spark further interest in the adoption of Dyadic’s C1 technology.”
    Dyadic is committed to enabling its partners and collaborators in the development of effective preventative and therapeutic treatments globally.
  • Dyadic is increasing global outreach to fulfill its mission to make a difference in global health by building an active pipeline through advancing its proprietary microbial platform technologies to create needed products such as recombinant human and bovine albumin and other biologic vaccines, antibodies, and products.